Key Takeaways Even as smart ring maker Oura prepares to enter the public markets, a proposed class action lawsuit against Oura is raising new questions
The U.S. Food and Drug Administration approved the first at-home brain stimulation device for major depressive disorder in December 2025. Nine months later, a systematic
A commission of practicing National Health Service (NHS) clinicians has proposed a new regulatory framework for artificial intelligence in healthcare, advocating for provisional authorization markers
Key Takeaways on Digital Suicide Prevention Wearable sensors, smartphones, and artificial intelligence (AI) are providing researchers with new ways to study suicide risk beyond traditional
Key Takeaways: AI Cybersecurity Risks in Healthcare A cybersecurity incident involving hundreds of OpenAI artificial intelligence (AI) agents raises new questions about the security risks
Key Takeaways: DEA Telemedicine Special Registration Update The Drug Enforcement Administration (DEA) has moved its long-awaited telemedicine special registration rule into final White House review,
